Dr. Berry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St Fl 8
Boston, MA 02114Phone+1 617-724-3914
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2006 - 2009
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2005 - 2006
Northwestern University The Feinberg School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2009 - 2025- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers Start of enrollment: 2011 Nov 01
- Gilenya in Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
- Longitudinal Study of Outcomes Measures in ALS Trials Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 127 citationsBulbar and speech motor assessment in ALS: Challenges and future directionsJordan R. Green, Yana Yunusova, Mili S. Kuruvilla, Jun Wang, Gary L. Pattee
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2013-11-01 - 99 citationsLong-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosisSabrina Paganoni, Suzanne Hendrix, Samuel P. Dickson, Newman Knowlton, Eric A. Macklin
Muscle & Nerve. 2021-01-01 - 60 citationsLongitudinal biomarkers in amyotrophic lateral sclerosis.Fen Huang, Yuda Zhu, Jennifer Hsiao-Nakamoto, Xinyan Tang, Jason C. Dugas
Annals of Clinical and Translational Neurology. 2020-07-01
Press Mentions
First Participant Enrolled in NIH-Funded Access for All in ALS ConsortiumAugust 12th, 2024- BrainStorm to Present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MNDNovember 23rd, 2020
- First Patient Enrolled in MTPA REFINE-ALS Biomarker StudyNovember 25th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
